Simultaneous multi-analyte urinary protein assay for bladder cancer detection.

Area of Science:

• Biomarker discovery and validation
• Clinical diagnostics
• Proteomics

Background:

• Multiplex protein assays enhance clinical efficiency.
• Bladder cancer diagnosis can be improved with accurate protein quantification.
• Urine-based biomarkers offer a non-invasive diagnostic approach.

Purpose of the Study:

• To evaluate the performance of a novel multiplex protein array (Q-plex) for quantifying bladder cancer biomarkers.
• To compare the diagnostic accuracy of the Q-plex assay with individual ELISA kits.
• To assess the utility of urine samples for bladder cancer biomarker detection.

Main Methods:

• Quantification of interleukin 8 (IL8), matrix metallopeptidase 9 (MMP9), and vascular endothelial growth factor A (VEGFA) using Q-plex and single-target ELISA kits.
• Analysis of urine samples from 73 subjects with known bladder cancer status.
• Evaluation of diagnostic accuracy, including AUROC, sensitivity, and specificity.

Main Results:

• The Q-plex assay achieved an AUROC of 0.9476, outperforming the combination of single-target ELISAs (AUROC 0.9119).
• Q-plex demonstrated a sensitivity of 0.93 and specificity of 0.81.
• Individual ELISAs showed a sensitivity of 0.77 and specificity of 0.91.

Conclusions:

• The Q-plex technology is a viable and efficient platform for multiplex protein quantification.
• This multiplex assay shows high accuracy for detecting bladder cancer-associated proteins in urine.
• Q-plex holds promise for improving diagnostic efficiency in clinical settings.